APA (7th ed.) Citation

AS, C., C, Y., DM, W., EF, P., LJ, v. '. V., D, Y., . . . AM, D. (2021). Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial. Nature communications, 12(1), 6428. https://doi.org/10.1038/s41467-021-26019-y

Chicago Style (17th ed.) Citation

AS, Clark, et al. "Neoadjuvant T-DM1/pertuzumab and Paclitaxel/trastuzumab/pertuzumab for HER2+ Breast Cancer in the Adaptively Randomized I-SPY2 Trial." Nature Communications 12, no. 1 (2021): 6428. https://doi.org/10.1038/s41467-021-26019-y.

MLA (9th ed.) Citation

AS, Clark, et al. "Neoadjuvant T-DM1/pertuzumab and Paclitaxel/trastuzumab/pertuzumab for HER2+ Breast Cancer in the Adaptively Randomized I-SPY2 Trial." Nature Communications, vol. 12, no. 1, 2021, p. 6428, https://doi.org/10.1038/s41467-021-26019-y.